Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Cohen Research PTSC Strong buy

 

 

We reach 98% of all institutional investors; 5+ million retail investors. We understand both retail and institutional research
distribution. Our performance record is in part a result of our powerful distribution program. Our institutional distribution
system and medium is similar to the major investment banking research firms such as Goldman Sachs.
• Our reports are accessed by those firms that collect institutional research including First Call’s Research Direct,
viewed by 98% of all institutions.
• Reuters, Multex and Yahoo reach 5+ million retail investors while 80+ data vendors including 300+ websites are
noticed of your report.
• 1.5 million opt - in blast email, 4 times within two months; third party.
• Bloomberg reaches 250,000+ institutional and sophisticated investors.
• Customized blast emails to selected 200,000+ investors, via a third party.
• Institutional salesmen call selected institutions.
• Your report is viewed free of charge on our powerful, heavily trafficked, unique website: www.cohenresearch.com.
We combine pricing, charting, trading data and analytics on 9,000+ companies, unique to the research industry.
• Our average hits on the date of report release are roughly 1,000.
• We believe our website has more financial content than any independent fundamental research firm. Our traffic is
growing all the time. In one day, one of our reports generated 25,000 hits and 4,676 downloads of an 80 page
report, creating record volume and price appreciation.
• Our reports often attract other Wall Street analysts for additional research coverage.
• I invite client and prospective companies to public events where I am invited as a guest speaker. It gives our client
and prospective companies exposure to institutional and retail investors on a one on one basis.

Share
New Message
Please login to post a reply